Genentech Used IP To Form $1B Monopoly, HGS Says

Law360, New York (February 23, 2011, 11:13 PM EST) -- Human Genome Sciences on Friday accused Genentech Inc. in federal court in Delaware of conspiring with Celltech R&D Ltd. to fraudulently obtain an antibody patent in order to create a monopoly and score more than $1 billion in royalties.

HGS launched its suit against Genentech in the U.S. District Court for the District of Delaware, claiming Celltech agreed in 2001 to sacrifice its patent in exchange for a share of Genentech's royalties under a patent covering the same invention.

The patents cover technology that uses recombinant...
To view the full article, register now.